Table 1 Basic information of NSCLC patients for model construction and model validation

Age

63.48 ± 9.57

63.33 ± 9.54

− 0.128^a

Gender

0.692^b

Male

137

66

Female

87

34

Smoking history

0.481^b

No

128

53

Yes

96

47

SUVmax of mediastinal lymph node

1.87 (1.41, 3.29)

2.03 (1.41, 3.76)

11,625.00^d

Primary-tumor SUVmax

7.13 (3.05, 11.28)^c

7.46 (2.78, 11.91)

11,572.50^d

Primary-tumor SUVpeak

4.48 (2.11, 7.33)^c

5.14 (2.00, 8.31)

11,546.00^d

Primary-tumor SUVmean

4.20 (1.78, 6.82)^c

4.35 (1.57, 7.15)

11,528.00^d

Primary-tumor MTV

16.51 (9.14, 35.75)^c

15.73 (9.14, 37.65)

11,164.50^d

Primary-tumor TLG

53.99 (19.15, 228.81)^c

57.43 (19.65, 244.25)

11,313.00^d

Primary tumor size (mm)

28.00 (20.00, 40.00)^c

27.50 (20.00, 38.00)

11,350.00^d

CEA

3.24 (1.95, 5.63)^c

3.07 (1.98, 5.12)

10,935.00^d

CYFRA21-1

2.83 (2.10, 4.14)^c

2.66 (2.07, 3.96)

10,731.50^d

CA19-9

11.22 (8.21, 17.30)^c

10.47 (7.26, 17.26)

10,465.00^d

SCC

0.93 (0.70, 1.40)^c

1.00 (0.73, 1.40)

11,502.50^d

NSE

13.05 (11.31, 15.63)^c

12.89 (10.79, 15.60)

10,691.50^d

TPA

87.56 (63.19, 134.98)^c

82.26 (63.15, 129.53)

10,948.50^d

proGRP

43.55 (34.30, 54.16)^c

44.87 (35.64, 55.24)

11,837.50^d

EGFR mutation

0.589^b

No

166

70

Yes

58

30

ALK rearrangement

0.238^b

No

205

95

Yes

14

5